Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
- Conditions
- Retinal DiseaseGenotype
- Registration Number
- NCT01145196
- Lead Sponsor
- National Eye Institute (NEI)
- Brief Summary
Background:
- Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called plaquenil-induced retinal toxicity, which may lead to vision loss. However, most people taking plaquenil do not develop this problem. Researchers are interested in studying whether differences in a person s genes explain why some people develop plaquenil-induced retinal toxicity while others do not.
Objectives:
- To investigate possible correlations between certain genes or genetic mutations and plaquenil-induced retinal toxicity.
Eligibility:
* Individuals at least 18 years of age who have previously used plaquenil.
* Both individuals who have and have not developed plaquenil-induced retinal toxicity will be eligible for this study.
Design:
* The study requires one or two visits to the National Eye Institute or an outpatient study clinic over a maximum 2-year period.
* Participants will provide a personal and family medical history, and will have a full eye examination.
* Participants will also provide blood samples for testing.
* No treatment will be provided as part of this protocol.
- Detailed Description
OBJECTIVE:
The objective of this study is to investigate whether there is a correlation between genetic mutations, beginning with an analysis of ABCA4, and Plaquenil(R)-induced retinal toxicity and to describe the phenotype of Plaquenil(R)-induced retinal toxicity.
STUDY POPULATION:
The study will enroll 100 patients, 18 years of age or older, found to have Plaquenil(R)-induced retinal toxicity. 200 volunteers with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or Sj(SqrRoot)(Delta)gren s syndrome and history of Plaquenil(R) use, but without evidence of retinal toxicity, will also be recruited.
DESIGN:
The study is an observational study with 1-2 outpatient visits to the NEI clinic or review of medical records for off-site participants. All participants will provide a blood sample for genetic analysis.
OUTCOME MEASURES:
Clinical examination and blood samples will be used for genetic testing and mutation identification. The primary outcome of this study is to identify genetic mutations, starting with those in ABCA4 gene, associated with retinal toxicity in participants with a history of Plaquenil(R) use. Secondary objectives include determining the utility of testing metrics in evaluating the presence of retinal toxicity.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The outcome of this study is to identify genetic mutations, starting with those in ABCA4 gene, associated with retinal toxicity in participants with a history of plaquenil use. annually for five years The outcome of this study is to identify genetic mutations, starting with those in ABCA4 gene, associated with retinal toxicity in participants with a history of plaquenil use.
- Secondary Outcome Measures
Name Time Method The secondary outcome of this study is to determine the utility of various testing metrics in evaluating the presence of retinal toxicity. annually for five years The secondary outcome of this study is to determine the utility of various testing metrics in evaluating the presence of retinal toxicity.
Trial Locations
- Locations (1)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States